ICT 08
Alternative Names: ICT-08Latest Information Update: 03 Feb 2021
Price :
$50 *
At a glance
- Originator ImCheck Therapeutics
- Class Monoclonal antibodies
- Mechanism of Action T lymphocyte inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Autoimmune disorders
Most Recent Events
- 13 Jan 2021 Early research in Autoimmune disorders in France (Parenteral) (ImCheck Therapeutics pipeline, January 2021)